What are the most common side effects of EFBEMALENOGRASTIM ALFA-VUXW?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for EFBEMALENOGRASTIM ALFA-VUXW. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is EFBEMALENOGRASTIM ALFA-VUXW the same as RYZNEUTA?

RYZNEUTA is a brand name for EFBEMALENOGRASTIM ALFA-VUXW. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

EFBEMALENOGRASTIM ALFA-VUXW

Q: What is EFBEMALENOGRASTIM ALFA-VUXW used for?

EFBEMALENOGRASTIM ALFA-VUXW (brand name RYZNEUTA) is a Other indicated for 1. INDICATIONS AND USAGE RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, as manifested by febrile neutropenia.

Q: How does EFBEMALENOGRASTIM ALFA-VUXW work?

EFBEMALENOGRASTIM ALFA-VUXW works through the following mechanism: 12.1 Mechanism of Action Efbemalenograstim alfa-vuxw is a colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation..

Other

Brand names: RYZNEUTA

Subcutaneous

Mechanism of Action

12.1 Mechanism of Action Efbemalenograstim alfa-vuxw is a colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.

Indications

1. INDICATIONS AND USAGE RYZNEUTA is indicated to decrease the incidence of infection

as manifested by febrile neutropenia

Contraindications

• 4. CONTRAINDICATIONS RYZNEUTA is contraindicated in patients with a history of serious allergic reactions to granulocyte stimulating factors such as efbemalenograstim alfa-vuxw
• pegfilgrastim
• or filgrastim products [see Warnings and Precautions ( 5.3 )] . Patients with a history of serious allergic reactions to granulocyte stimulating factors such as efbemalenograstim alfa-vuxw
• pegfilgrastim
• or filgrastim products. ( 4 )

FDA Warnings

WARNINGS AND PRECAUTIONS Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture
2 ) Serious allergic reactions, including anaphylaxis: Permanently discontinue RYZNEUTA in patients with serious allergic reactions
1 Splenic Rupture Splenic rupture, including fatal cases, can occur following the administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) products, such as RYZNEUTA
3 Serious Allergic Reactions Serious allergic reactions, including anaphylaxis, can occur in patients receiving rhG-CSF products, such as RYZNEUTA

Known Side Effects

9 documented side effects by frequency

Weakness

>10%

Shortness of Breath

>10%

Fever

>10%

Nausea

1-10%

Dizziness

1-10%

Excessive Sweating

1-10%

Heart Palpitations

1-10%

Vomiting

1-10%

Abdominal Pain

0.1-1%

Community Discussions

No community discussions found for EFBEMALENOGRASTIM ALFA-VUXW yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → EFBEMALENOGRASTIM ALFA-VUXW openFDA label JSON → EFBEMALENOGRASTIM ALFA-VUXW FAERS adverse-event reports → EFBEMALENOGRASTIM ALFA-VUXW ClinicalTrials.gov → completed Phase 2+ trials of EFBEMALENOGRASTIM ALFA-VUXW

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Subcutaneous